SCHEDULE 13G/A: BlackRock Discloses 7.8% Stake in MaxCyte, Inc.
Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 7.8% of MaxCyte, Inc.'s common stock as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 8,256,000 shares of MaxCyte, Inc. common stock.
- This represents 7.8% of MaxCyte, Inc.'s total outstanding common stock.
- BlackRock holds sole voting power over 8,127,761 shares and sole dispositive power over 8,256,000 shares.
- The filing is an Amendment No. 4 to Schedule 13G, indicating an update to a previously reported ownership stake.
- The event date requiring this filing was December 31, 2024, with the filing submitted on February 5, 2025.
- BlackRock, Inc. is classified as a parent holding company (HC) for the purpose of this filing.
- BlackRock Investment Management, LLC is identified as a subsidiary that beneficially owns 5% or greater of MaxCyte's outstanding shares.
Sentiment
Score: 6
Explanation: The document is a routine ownership disclosure. The presence of a significant institutional investor like BlackRock is generally viewed as a neutral to slightly positive signal, indicating continued institutional interest in the company. No negative information is presented within the filing itself.
Positives
- The presence of a major institutional investor like BlackRock, Inc. holding a significant stake (7.8%) can signal institutional confidence or interest in MaxCyte, Inc.'s business.
- A substantial institutional holding may contribute to stock stability and liquidity.
Future Outlook
This document is an ownership disclosure and does not contain forward-looking statements or guidance regarding MaxCyte, Inc.'s future performance or outlook.
Industry Context
MaxCyte, Inc. operates in the biotechnology and life sciences sector, focusing on cell engineering. BlackRock's significant investment reflects broader institutional interest in companies within this innovative and potentially high-growth industry, which is driven by advancements in cell therapies and related biotechnologies.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holding provides transparency regarding the company's ownership structure and may influence investor sentiment and confidence.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which has been expressly revoked by the new Power of Attorney. |
| 2024-12-31 | Date of the event which required the filing of this Schedule 13G statement. |
| 2025-01-21 | Date of execution for the new Power of Attorney, effective from this date. |
| 2025-02-05 | Date of filing of this Schedule 13G Amendment No. 4. |
Keywords
MaxCyte, BlackRock, Schedule 13G, Common Stock, Institutional Ownership, Biotechnology, Life Sciences, SEC Filing, Ownership Disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.